Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial

Autor: Penalver, Francisco-Javier, Marquez, Jose-Antonio, Duran, Soledad, Giraldo, Pilar, Martin, Alejandro, Montalban, Carlos, Sancho, Juan-Manuel, Ramirez, Maria-Jose, Terol, Maria-Jose, Capote, Francisco-Javier, Gutierrez, Antonio, Sanchez, Blanca, Lopez, Andres, Salar, Antonio, Rodriguez-Caravaca, Gil, Canales, Miguel, Caballero, Maria-Dolores, Bello Lopez, Jose Luis, Carbonell, Felix, Ferrer Bordas, Secundino, Font Lopez, Patricia, Perez Persona, Ernesto, Lopez Guillermo, Armando, Hernandez Martin, Roberto, Ramon Mayans, Jose, Palomera, Luis, Perez Ceballos, Elena, Queizan Hernandez, Jose Antonio, Riaza Grau, Rosalia, de la Cruz, Fatima, Sanchez Salinas, Andres, GELTAMO Spanish Lymphoma Cooperati

Publikováno v: Cancer medicine
r-FISABIO: Repositorio Institucional de Producción Científica
Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO)
Cancer Medicine. 2019;00:1–13.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
instname
Scientia
Cancer Medicine
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
Cancer Medicine, Vol 8, Iss 16, Pp 6955-6966 (2019)

Background Consensus is lacking regarding the optimal salvage therapy for patients with follicular lymphoma who relapse after or are refractory to immunochemotherapy. Methods This phase II trial evaluated the efficacy and safety of response‐adapted

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b016266cc0c27999365889288230dbc8
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=7284